 |
|
Synthesis and Metabolism of Radioactive Heparin
HAROLD B. EIBER, M.D.;
ISIDORE DANISHEFSKY, Ph.D.
AMA Arch Intern Med. 1958;102(2):189-193.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
Introduction
Heparin synthesis, metabolism, and fate has been an enigma for many years. The following paper is based on the results of a three-year biochemical and clinical study of this fascinating substance. New methods of study were established, including the synthesis and experimental use of radioactive heparin in an effort to elucidate its many problems.
Heparin has been employed clinically for a number of years in the treatment of thrombosis. The rationale for its application is the fact that it is an extremely potent inhibitor of blood coagulation, and consequently it may be expected to be beneficial in thromboembolic diseases. Its effect as an anticoagulant is almost immediate, and it is therefore extremely useful where rapid action is required.1 Heparin acts primarily on one of the later stages of blood coagulation, i. e., it inhibits the formation of thrombin from prothrombin and, to some extent, prevents thrombin from converting
. . . [Full Text PDF of this Article]
Author Affiliations
New York
The Gilman Laboratory is a part of New York Medical College, Flower and Fifth Avenue Hospitals. Department of Medicine (Dr. Eiber) and Department of Biochemistry (Dr. Danishefsky).
Footnotes
Submitted for publication Dec. 28, 1957.
This study was supported by grants from the National Heart Institute (U. S. P. H. S.) and the Atomic Energy Commission.
Prepared from a scientific exhibit shown in the Section on Experimental Medicine and Therapeutics at the 106th Annual Meeting of the American Medical Association, New York, June 3-7, 1957.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
